228 related articles for article (PubMed ID: 30021875)
41. Inhibition of mTORC1 inhibits lytic replication of Epstein-Barr virus in a cell-type specific manner.
Adamson AL; Le BT; Siedenburg BD
Virol J; 2014 Jun; 11():110. PubMed ID: 24917448
[TBL] [Abstract][Full Text] [Related]
42. New insight into Epstein-Barr virus infection using models of stratified epithelium.
Hayman IR; Temple RM; Burgess CK; Ferguson M; Liao J; Meyers C; Sample CE
PLoS Pathog; 2023 Jan; 19(1):e1011040. PubMed ID: 36630458
[TBL] [Abstract][Full Text] [Related]
43. 5-hydroxymethylation of the EBV genome regulates the latent to lytic switch.
Wille CK; Nawandar DM; Henning AN; Ma S; Oetting KM; Lee D; Lambert P; Johannsen EC; Kenney SC
Proc Natl Acad Sci U S A; 2015 Dec; 112(52):E7257-65. PubMed ID: 26663912
[TBL] [Abstract][Full Text] [Related]
44. Epstein-Barr Virus Infection of Pseudostratified Nasopharyngeal Epithelium Disrupts Epithelial Integrity.
Yu F; Lu Y; Li Y; Uchio Y; Pangnguriseng UA; Kartika AV; Iizasa H; Yoshiyama H; Loh KS
Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32972034
[TBL] [Abstract][Full Text] [Related]
45. Suppression of Epstein-Barr virus DNA load in latently infected nasopharyngeal carcinoma cells by CRISPR/Cas9.
Yuen KS; Wang ZM; Wong NM; Zhang ZQ; Cheng TF; Lui WY; Chan CP; Jin DY
Virus Res; 2018 Jan; 244():296-303. PubMed ID: 28456574
[TBL] [Abstract][Full Text] [Related]
46. Reactivation of Epstein-Barr Virus by HIF-1α Requires p53.
Kraus RJ; Cordes BA; Sathiamoorthi S; Patel P; Yuan X; Iempridee T; Yu X; Lee DL; Lambert PF; Mertz JE
J Virol; 2020 Aug; 94(18):. PubMed ID: 32641480
[TBL] [Abstract][Full Text] [Related]
47. Pharmacologic Activation of Lytic Epstein-Barr Virus Gene Expression without Virion Production.
Lee J; Kosowicz JG; Hayward SD; Desai P; Stone J; Lee JM; Liu JO; Ambinder RF
J Virol; 2019 Oct; 93(20):. PubMed ID: 31341058
[TBL] [Abstract][Full Text] [Related]
48. Epstein-Barr virus-epithelial cell interaction and its implication in the etiology of nasopharyngeal carcinoma.
Lenoir G; de-The G
IARC Sci Publ (1971); 1978; (20):377-84. PubMed ID: 215520
[TBL] [Abstract][Full Text] [Related]
49. Inhibition of Epstein-Barr virus infection by lactoferrin.
Zheng Y; Zhang W; Ye Q; Zhou Y; Xiong W; He W; Deng M; Zhou M; Guo X; Chen P; Fan S; Liu X; Wang Z; Li X; Ma J; Li G
J Innate Immun; 2012; 4(4):387-98. PubMed ID: 22433582
[TBL] [Abstract][Full Text] [Related]
50. Inhibition of class I histone deacetylases by romidepsin potently induces Epstein-Barr virus lytic cycle and mediates enhanced cell death with ganciclovir.
Hui KF; Cheung AK; Choi CK; Yeung PL; Middeldorp JM; Lung ML; Tsao SW; Chiang AK
Int J Cancer; 2016 Jan; 138(1):125-36. PubMed ID: 26205347
[TBL] [Abstract][Full Text] [Related]
51. Epstein-Barr virus mRNA profiles and viral DNA methylation status in nasopharyngeal brushings from nasopharyngeal carcinoma patients reflect tumor origin.
Ramayanti O; Juwana H; Verkuijlen SA; Adham M; Pegtel MD; Greijer AE; Middeldorp JM
Int J Cancer; 2017 Jan; 140(1):149-162. PubMed ID: 27600027
[TBL] [Abstract][Full Text] [Related]
52. Luteolin inhibits Epstein-Barr virus lytic reactivation by repressing the promoter activities of immediate-early genes.
Wu CC; Fang CY; Hsu HY; Chen YJ; Chou SP; Huang SY; Cheng YJ; Lin SF; Chang Y; Tsai CH; Chen JY
Antiviral Res; 2016 Aug; 132():99-110. PubMed ID: 27185626
[TBL] [Abstract][Full Text] [Related]
53. Epstein-Barr virus infection of Langerhans cell precursors as a mechanism of oral epithelial entry, persistence, and reactivation.
Walling DM; Ray AJ; Nichols JE; Flaitz CM; Nichols CM
J Virol; 2007 Jul; 81(13):7249-68. PubMed ID: 17376908
[TBL] [Abstract][Full Text] [Related]
54. Human papillomavirus promotes Epstein-Barr virus maintenance and lytic reactivation in immortalized oral keratinocytes.
Makielski KR; Lee D; Lorenz LD; Nawandar DM; Chiu YF; Kenney SC; Lambert PF
Virology; 2016 Aug; 495():52-62. PubMed ID: 27179345
[TBL] [Abstract][Full Text] [Related]
55. A Mechanism-Based Targeted Screen To Identify Epstein-Barr Virus-Directed Antiviral Agents.
Li X; Akinyemi IA; You JK; Rezaei MA; Li C; McIntosh MT; Del Poeta M; Bhaduri-McIntosh S
J Virol; 2020 Oct; 94(21):. PubMed ID: 32796077
[TBL] [Abstract][Full Text] [Related]
56. Patterned entry and egress by Epstein-Barr virus in polarized CR2-positive epithelial cells.
Chodosh J; Gan Yj; Holder VP; Sixbey JW
Virology; 2000 Jan; 266(2):387-96. PubMed ID: 10639323
[TBL] [Abstract][Full Text] [Related]
57. Epstein-Barr virus (EBV) reactivation and therapeutic inhibitors.
Kerr JR
J Clin Pathol; 2019 Oct; 72(10):651-658. PubMed ID: 31315893
[TBL] [Abstract][Full Text] [Related]
58. Activation of the FGFR1 signalling pathway by the Epstein-Barr virus-encoded LMP1 promotes aerobic glycolysis and transformation of human nasopharyngeal epithelial cells.
Lo AK; Dawson CW; Young LS; Ko CW; Hau PM; Lo KW
J Pathol; 2015 Oct; 237(2):238-48. PubMed ID: 26096068
[TBL] [Abstract][Full Text] [Related]
59. IFIT3 inhibits Epstein-Barr virus reactivation via upregulating innate immunity.
Zhang W; Jiang M; Liao X; Li Y; Xin S; Yang L; Xin Y; Umar A; Lu J
J Med Virol; 2023 Nov; 95(11):e29237. PubMed ID: 37994186
[TBL] [Abstract][Full Text] [Related]
60. [Epstein-Barr virus (
Yakushina SA; Kisteneva LB
Vopr Virusol; 2020 Sep; 65(4):191-202. PubMed ID: 33533222
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
